Siemens Healthineers and Prisma Health expanded their Value Partnership to improve the quality of cancer care in Tennessee and South Carolina. The collaboration will focus on deploying advanced imaging as well as therapy technologies to enhance early diagnosis and treatment outcomes.
Prisma Health is investing $50 million to acquire the Ethos adaptive radiotherapy system from Varian, a Siemens Healthineers company. This move aims to provide more personalized cancer treatment for patients.
Adaptive radiotherapy uses AI-driven treatment and planning to adjust to tumor and anatomical changes in real time. This ensures more precise, personalized cancer care while protecting healthy tissue.
Prisma Health and Siemens Healthineers entered into a 10-year Value Partnership in 2021. The main aim of this collaboration was to promote innovation, improve care, and develop local workforce.
The expanded partnership will incorporate next-generation technology, specialized clinical oncology expertise, professional services, innovative tools, and time-saving workflows. Its goal is to deliver more personalized, efficient, and accessible care to Prisma Health’s communities.
Views and Statements
In the words of Clarence Sevillian, EVP and COO of Prisma Health, “Through our Value Partnership with Siemens Healthineers, we have expanded access to imaging services and introduced new technologies and care sites to better serve our communities.”
He further added, “Our top priority is to ensure that patients have access to care that is compassionate and informed by the latest clinical insights. This next phase deepens collaboration, integrating advanced oncology tools to streamline operations and improve patient care.”
John Kowal, president at Siemens Healthineers, said, “Partnering with Prisma Health to deliver end-to-end cancer care is a proud milestone. Integrating diagnostic imaging, radiation therapy, and post-treatment monitoring with expert services to manage complex oncology operations ensures consistent and sustainable advancements in patient care over time.”
Impact and Future Outlook
The $50 million investment by Prisma Health in adaptive radiotherapy technology marks a significant advancement in the radiotherapy industry. This collaboration enhances the precision as well as personalization of cancer treatment by integrating the AI-driven Ethos system from Varian.
It also sets a new benchmark for adaptive radiotherapy deployment across healthcare systems. The move reflects a growing trend toward AI-powered, patient-specific oncology solutions that improve treatment outcomes as well as enhance operational efficiency.
Such high-value partnerships are expected to increase adoption of next-generation radiotherapy technologies. It will fuel innovation in oncology care and reshape competitive dynamics in the radiotherapy sector.
According to Coherent Market Insights (CMI), the global radiotherapy market is projected to expand at a CAGR of 7.3% during the forecast period. Total industry valuation will likely increase from USD 8.55 Bn in 2025 to USD 14.01 Bn by 2032.
Source:
Company: Siemens Healthineers
